RTTNews | Oct 12, 2020 07:12AM EDT

07:11 Monday, October 12, 2020 (RTTNews.com) - Bausch Health Companies Inc. (BHC, BHC.TO), Bausch + Lomb, and Eyenovia, Inc., (EYEN) announced that an affiliate of Bausch Health has acquired an exclusive license in the United States and Canada for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, in children ages 3-12. The investigational formulation of atropine is delivered with Eyenovia's Optejet dispenser technology.

Bausch Health will make an upfront $10 million payment to Eyenovia upon signing and will assume oversight and costs related to the ongoing phase 3 CHAPERONE trial. Eyenovia is eligible to receive up to $35 million in additional payments based on approval- and launch-based milestones, as well as royalties.

Read the original article on RTTNews ( https://www.rttnews.com/3135439/bausch-health-acquires-license-for-investigational-atropine-ophthalmic-solution.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved